NCT07042191 A Provider Intervention to Reduce Financial Toxicity in Patients With Cancer Through Improved Treatment Cost Discussions
| NCT ID | NCT07042191 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Barbara Ann Karmanos Cancer Institute |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2022-12-09 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2022-12-09 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goal of this research program is to address financial toxicity through the development, testing, and implementation of a multi-level communication intervention. If successful, this intervention could be a companion intervention for Cancer providers in combination with the already in testing DISCO app (Discussions of Cost App) for patients. Participants will: * complete a baseline survey * attend two one on one meetings, one as part of the development and the second as part of the pilot testing of the intervention.
Eligibility Criteria
Inclusion Criteria: * Oncology care providers at Karmanos Cancer Institute (KCI)/Wayne State University(WSU) including medical oncologists, nurses, social workers and advance practice providers who treat cancer patients at KCI Detroit or Farmington Hills clinics Exclusion Criteria: \-
Contact & Investigator
Lauren M Hamel, PhD
PRINCIPAL INVESTIGATOR
Wayne State University
Frequently Asked Questions
Who can join the NCT07042191 clinical trial?
This trial is open to participants of all sexes, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07042191 currently recruiting?
Yes, NCT07042191 is actively recruiting participants. Contact the research team at hamell@karmanos.org for enrollment information.
Where is the NCT07042191 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT07042191 clinical trial?
NCT07042191 is sponsored by Barbara Ann Karmanos Cancer Institute. The principal investigator is Lauren M Hamel, PhD at Wayne State University. The trial plans to enroll 20 participants.